LenioBio and Twist Bioscience have entered into a collaboration aimed at advancing AI-driven drug discovery by accelerating protein expression and experimental validation workflows. The partnership combines LenioBio’s ALiCE® cell-free protein expression platform with Twist Bioscience’s DNA manufacturing and automation capabilities to speed up the design-build-test cycle used in biologics and antibody development. By enabling rapid generation of experimental data from real-world protein molecules, the collaboration seeks to improve the performance of AI models through faster lab-in-the-loop iterations. The ALiCE® platform can produce full-length, functional proteins within 24 hours, reducing delays between computational design and wet-lab validation while supporting complex molecules with eukaryotic characteristics.
Also Read: Roche Expands AI Capabilities with NVIDIA-Powered Factory to Accelerate Drug Discovery
“AI can design new protein molecules for biologic drugs: the problem is that reality doesn’t always reflect what the computer imagines,” said André Goerke, CEO of LenioBio. “Bringing together Twist’s highly automated manufacturing and characterization capabilities with LenioBio’s ALiCE® system for cell-free protein expression, can enable rapid data generation from real-world molecules.” The companies believe the collaboration will help accelerate AI-led antibody development and improve experimental accuracy in biologics research.